Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11857627-B2
Publication Date
2024-01-02
Expiration Date
Abstract
A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.
Core Innovation
The patent describes oxygen-therapeutic treatment for radiotherapy using a water-based fluorocarbon emulsion administered intravenously prior to each fraction of radiation therapy, while the subject receives supplemental oxygen or carbogen. The approach is presented for fractionated radiotherapy, with the fluorocarbon emulsion administered concomitantly or within a stated time window before each radiation fraction. The fluorocarbon is described as perfluoropentane in a water emulsion comprising a fluorosurfactant and a specified perfluoropentane content.
The patent focuses on using a perfluoropentane emulsion containing a fluorosurfactant and about 1% to 10% w/vol of perfluoropentane. It further defines that the emulsion is administered at a dosage in the range from about 0.05 cc/kg to about 0.3 cc/kg. The patent additionally specifies that the subject simultaneously receives carbogen or supplemental oxygen during the multi-fraction radiotherapy schedule.
The patent also describes extending the oxygen-therapeutic approach to glioblastoma by combining the multi-fraction radiotherapy or chemotherapy protocol with administration of the perfluoropentane water emulsion and simultaneous carbogen or supplemental oxygen. The document further states that the solid hypoxic tumor treatment is applicable to solid hypoxic tumors selected from a listed group of tumor types, using multi-fraction radiotherapy with administration of the perfluoropentane water emulsion concomitantly or up to 120 minutes prior to each radiation fraction.
Claims Coverage
The provided independent claims are clm-00001 and clm-00009. Across these, the claim set contains 5 inventive features related to time-synchronized intravenous administration of a perfluoropentane water emulsion with a fluorosurfactant, simultaneous administration of carbogen or supplemental oxygen, and multi-fraction radiotherapy treatment targeting glioblastoma or selected solid hypoxic tumors, with dose and composition constraints.
Time-synchronized perfluoropentane water emulsion for multi-fraction glioblastoma radiotherapy or chemotherapy
A method of treating glioblastoma by multi-fraction radiotherapy or chemotherapy comprising concomitantly or up to 120 minutes prior to each fraction administering to the subject a water emulsion of perfluoropentane to the mammal, wherein the perfluoropentane emulsion comprises a fluorosurfactant and about 1% to 10% w/vol of perfluoropentane.
Simultaneous carbogen or supplemental oxygen with perfluoropentane emulsion
Simultaneously administering the mammal carbogen or supplemental oxygen during the multi-fraction radiotherapy or chemotherapy treatment using the perfluoropentane emulsion.
Perfluoropentane emulsion dose range for fraction-based treatment
Administering the perfluoropentane emulsion at a dosage in the range from about 0.05 cc/kg to about 0.3 cc/kg.
Perfluoropentane emulsion for multi-fraction radiotherapy of solid hypoxic tumors
A method of treating solid hypoxic tumors by multi-fraction radiotherapy comprising administering to a subject suffering from a solid hypoxic tumor, concomitantly or up to 120 minutes prior to each fraction, a water emulsion of perfluoropentane to the mammal, wherein the perfluoropentane emulsion comprises a fluorosurfactant and about 1% to 10% w/vol of perfluoropentane.
Selected solid hypoxic tumor types for multi-fraction radiotherapy
Selecting the solid hypoxic tumor from pancreatic cancer, non-small cell lung cancer, cervical carcinoma, squamous cell carcinoma, ovarian cancer, sarcoma, multiple myeloma, prostate cancer, rectal cancer, Wilms tumor, head and neck cancer, oral carcinoma and uterine carcinoma.
The independent claims cover oxygen-therapeutic fraction-based cancer treatment in which a perfluoropentane water emulsion with a fluorosurfactant is administered concomitantly or up to 120 minutes prior to each radiation fraction, with simultaneous carbogen or supplemental oxygen for glioblastoma, and with multi-fraction radiotherapy for selected solid hypoxic tumor types. Dose and composition constraints are specified for the perfluoropentane emulsion, including perfluoropentane w/vol content and, for clm-00001, a dosage range in cc/kg.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Multi-fraction radiotherapy or chemotherapy treatment of glioblastoma.
Multi-fraction radiotherapy treatment of solid hypoxic tumors selected from pancreatic cancer, non-small cell lung cancer, cervical carcinoma, squamous cell carcinoma, ovarian cancer, sarcoma, multiple myeloma, prostate cancer, rectal cancer, Wilms tumor, head and neck cancer, oral carcinoma, and uterine carcinoma.
Interested in licensing this patent?